News & Updates
Filter by Specialty:
Apremilast safe, effective in moderate-to-severe genital psoriasis
Treatment with apremilast demonstrates consistent efficacy in genital psoriasis and overall psoriasis symptoms at 16 weeks irrespective of body surface area (BSA) at baseline, suggest the results of the phase III DISCREET trial presented at the recent AAD 2023.
Apremilast safe, effective in moderate-to-severe genital psoriasis
13 Apr 2023
Mirabegron may improve sexual function in adults with OAB
Mirabegron, a ß3 adrenoceptor agonist, delivers benefit for both men and women with overactive bladder (OAB) who are experiencing sexual dysfunction, a systematic review and meta-analysis reports.
Mirabegron may improve sexual function in adults with OAB
13 Apr 2023
Lebrikizumab helps clear skin of teens with moderate-to-severe atopic dermatitis
Treatment with lebrikizumab with or without topical corticosteroids (TCS) results in clinical improvement among adolescents with moderate-to-severe atopic dermatitis (AD), according to a study presented at the recent AAD 2023.
Lebrikizumab helps clear skin of teens with moderate-to-severe atopic dermatitis
12 Apr 2023
COVID-19 vaccine perception poor among SG drivers
A substantial proportion of transport drivers in Singapore had poor vaccine perception, were hesitant to receive the COVID-19 vaccine, and were unwilling to receive the third dose (booster shot) despite the high vaccination coverage in the city-state, a cross-sectional pilot study reports.
COVID-19 vaccine perception poor among SG drivers
12 Apr 2023
Early addition of cerebrolysin to reperfusion therapy reduces haemorrhagic transformation after ischaemic stroke
A prospective, randomized, multicentre pilot study finds that early addition of cerebrolysin to reperfusion therapy is safe and significantly reduces the rate of haemorrhagic transformation (HT) after acute ischaemic stroke (AIS).
